| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Kidney (Neoplasm)SunitinibBevacizumabSorafenibTemsirolimusThyroid (Neoplasia)AxitinibPazopanibVadetanibXL184MotesanibEverolimusVEGFPegaptanibRanibizumab| 1 | 2010 | Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. | 
| + | - | nl | Health Technol Assess 14(2):1-184, iii-iv (2010) |
| 2 | 2008 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. |
| + | - | nl | Mol Cancer Ther 7(10):3129-40 (2008) |
| 3 | 2007 | Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. |
| + | - | nl | Ann Oncol 18 Suppl 6(-):vi22-5 (2007) |
| 4 | 2007 | CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. |
| + | - | nl | Clin Cancer Res 13(13):3765-70 (2007) |
| 5 | 2006 | Sorafenib for the treatment of advanced renal cell carcinoma. |
| + | - | nl | Clin Cancer Res 12(24):7271-8 (2006) |
| 6 | 2011 | Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. |
| + | - | nl | Endocr J 58(3):151-3 (2011) |
| 7 | 2010 | Targeted therapy for renal cell cancer: current perspectives. |
| + | - | nl | Discov Med 10(54):394-405 (2010) |
| 8 | 2007 | Vascular endothelial growth factor: biology and therapeutic applications. |
| + | - | nl | Int J Biochem Cell Biol 39(7-8):1349-57 (2007) |
| 9 | 2008 | Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. |
| + | - | nl | Oncologist 13(8):845-58 (2008) |
| 10 | 2009 | Sorafenib and sunitinib. |
| + | - | nl | Oncologist 14(8):800-5 (2009) |
| 11 | 2010 | Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. |
| + | - | nl | Isr Med Assoc J 12(10):628-32 (2010) |
